Vivos Inc. (RDGL)

Market Cap	38.44M -37.2%
Revenue (ttm)	48.62K +111.4%
Net Income	-3.01M
EPS	-0.01
Shares Out	455.54M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,400
Average Volume	569,412
Open	0.0822
Previous Close	0.0849
Day's Range	0.0810 - 0.0836
52-Week Range	0.0425 - 0.1657
Beta	-0.59
RSI	56.72
Earnings Date	Feb 27, 2026

About Vivos

Vivos Inc., a radiation oncology medical device company, develops brachytherapy devices for the treatment of non-resectable tumors in the United States. The company develops an yttrium-90 based precision radionuclide therapy device; RadioGel, which is an injectable particle-gel for Precision Radionuclide Therapy radiation treatment of cancerous tumors in people and animals; and IsoPet for the treatment of solid tumors in animals. It is also developing a universal laboratory cooling device; hydrogel; and other products under the Alpha-Gel, Beta-...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1994
• Employees: 1
• Stock Exchange: OTCMKTS
• Ticker Symbol: RDGL

Financial Performance

In 2024, Vivos's revenue was $27,995, an increase of 43.56% compared to the previous year's $19,500. Losses were -$2.91 million, 0.54% more than in 2023.